First Time Loading...
T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 2 654.55 INR 0.91% Market Closed
Updated: May 16, 2024
Section:
 

Relative Value

The Relative Value of one TORNTPHARM stock under the Base Case scenario is 2 349.68 INR. Compared to the current market price of 2 654.55 INR, Torrent Pharmaceuticals Ltd is Overvalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TORNTPHARM Relative Value
Base Case
2 349.68 INR
Overvaluation 11%
Relative Value
Price
T
Worst Case
Base Case
Best Case

Valuation Multiples

8.6
P/S
P/S
Price to Sales
8.6
vs History
4
vs Industry
18
Median 3Y
6
Median 5Y
5.6
Industry
2.5
Forward
8.2
More Details
59.8
P/E
P/E
Price to Earnings
59.8
vs History
28
vs Industry
7
Median 3Y
51.7
Median 5Y
50.8
Industry
23.4
Forward
54.6
More Details
30.7
P/OCF
P/OCF
Price to OCF
30.7
vs History
7
vs Industry
15
Median 3Y
26.5
Median 5Y
25.4
Industry
17.9
More Details
34.7
P/FCFE
P/FCFE
Price to FCFE
34.7
vs History
61
vs Industry
16
Median 3Y
53
Median 5Y
53
Industry
24.1
More Details
13.4
P/B
P/B
Price to Book Value
13.4
vs History
4
vs Industry
4
Median 3Y
8.6
Median 5Y
8.2
Industry
2.1
More Details
8.7
EV/S
EV/S
Enterprise Value to Sales
8.7
vs History
4
vs Industry
16
Median 3Y
6.3
Median 5Y
5.8
Industry
2.6
Forward
8.3
More Details
11.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.7
vs History
4
vs Industry
18
Median 3Y
8.7
Median 5Y
8.1
Industry
5.2
More Details
28.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.5
vs History
4
vs Industry
12
Median 3Y
21.3
Median 5Y
20.9
Industry
13.9
Forward
26.2
More Details
37.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
37.8
vs History
4
vs Industry
11
Median 3Y
28.9
Median 5Y
27.3
Industry
17.5
Forward
34.7
More Details
31.1
EV/OCF
EV/OCF
Enterprise Value to OCF
31.1
vs History
7
vs Industry
15
Median 3Y
27.3
Median 5Y
26.8
Industry
16.4
More Details
36.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36.7
vs History
19
vs Industry
14
Median 3Y
33
Median 5Y
32.6
Industry
18.1
More Details
7.5
EV/IC
EV/IC
Enterprise Value to IC
7.5
vs History
4
vs Industry
12
Median 3Y
4.8
Median 5Y
4.5
Industry
1.9
More Details

Multiples Across Competitors

TORNTPHARM Competitors Multiples
Torrent Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
898.4B INR 8.6 59.8 28.5 37.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
744.4B USD 20.7 121.3 59.4 67.5
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.7 45.8 34.1 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.4B USD 4.3 9.5 11.8 15.4
US
Merck & Co Inc
NYSE:MRK
333.6B USD 5.4 144.7 36 58.8
UK
AstraZeneca PLC
LSE:AZN
188.7B GBP 5 37.5 174.5 278.3
CH
Novartis AG
SIX:NOVN
182.5B CHF 3.4 11.5 8.7 12.8
CH
Roche Holding AG
SIX:ROG
181.4B CHF 3.1 15.8 9 10.6
US
Pfizer Inc
NYSE:PFE
162.7B USD 3 -526.6 13 20.7
P/E Multiple
Earnings Growth
IN
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Average P/E: 55.7
59.8
109%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
121.3
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.8
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-20%
US
Merck & Co Inc
NYSE:MRK
144.7
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.5
168%
CH
Novartis AG
SIX:NOVN
11.5
15%
CH
Roche Holding AG
SIX:ROG
15.8
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -526.6
680%

See Also

Summary
TORNTPHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
TORNTPHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TORNTPHARM stock valuation using valuation multiples.
Wall Street Estimates
TORNTPHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TORNTPHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.